5 results match your criteria: "University Hospitals of North Midlands and Keele University[Affiliation]"
Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results.
Clin Cancer Res
April 2022
The Institute of Cancer Research, Clinical Trials and Statistics Unit, London, United Kingdom.
Article Synopsis
- The EPHOS-B trial aimed to evaluate the effects of perioperative anti-HER2 therapy on tumor growth and cell death in women with HER2-positive breast cancer before surgery.
- In a multicenter study involving 257 patients, various treatment groups including trastuzumab and lapatinib were tested, revealing that lapatinib led to a higher percentage of tumor response compared to trastuzumab or no treatment.
- The study found that early decreases in tumor proliferation (Ki67) are linked to better long-term outcomes, supporting a potential individualized approach to reduce treatment intensity for certain patients.
Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial.
Clin Cancer Res
July 2019
Cancer Insight, San Antonio, Texas.
Purpose: In phase I/II studies, nelipepimut-S (NP-S) plus GM-CSF vaccine was well tolerated and effectively raised HER2-specific immunity in patients with breast cancer. Results from a prespecified interim analysis of a phase III trial assessing NP-S + GM-CSF are reported.
Patients And Methods: This multicenter, randomized, double-blind phase III study enrolled females ≥18 years with T1-T3, HER2 low-expressing (IHC 1+/2+), node-positive breast cancer in the adjuvant setting.
Background: The clinical effectiveness of treating ipsilateral multifocal (MF) and multicentric (MC) breast cancers using breast-conserving surgery (BCS) compared with the standard of mastectomy is uncertain. Inconsistencies relate to definitions, incidence, staging and intertumoral heterogeneity. The primary aim of this systematic review was to compare clinical outcomes after BCS versus mastectomy for MF and MC cancers, collectively defined as multiple ipsilateral breast cancers (MIBC).
View Article and Find Full Text PDFPartial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial.
Lancet
September 2017
Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK.
Background: Local cancer relapse risk after breast conservation surgery followed by radiotherapy has fallen sharply in many countries, and is influenced by patient age and clinicopathological factors. We hypothesise that partial-breast radiotherapy restricted to the vicinity of the original tumour in women at lower than average risk of local relapse will improve the balance of beneficial versus adverse effects compared with whole-breast radiotherapy.
Methods: IMPORT LOW is a multicentre, randomised, controlled, phase 3, non-inferiority trial done in 30 radiotherapy centres in the UK.
Time for a randomised clinical trial evaluating breast conserving surgery compared to mastectomy in ipsilateral mutlifocal breast cancer (MFBC)?
Breast
April 2016
Breast Cancer Centre, University Hospitals of North Midlands and Keele University, Stoke on Trent ST4 6QG, UK.